Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 44

Cited In for PubMed (Select 19293179)

1.

Hypothesis: Artifacts, Including Spurious Chimeric RNAs with a Short Homologous Sequence, Caused by Consecutive Reverse Transcriptions and Endogenous Random Primers.

Peng Z, Yuan C, Zellmer L, Liu S, Xu N, Liao DJ.

J Cancer. 2015 May 1;6(6):555-67. doi: 10.7150/jca.11997. eCollection 2015. Review.

2.

Functional characterization of BC039389-GATM and KLK4-KRSP1 chimeric read-through transcripts which are up-regulated in renal cell cancer.

Pflueger D, Mittmann C, Dehler S, Rubin MA, Moch H, Schraml P.

BMC Genomics. 2015 Mar 27;16:247. doi: 10.1186/s12864-015-1446-z.

3.

Discovery of CTCF-sensitive Cis-spliced fusion RNAs between adjacent genes in human prostate cells.

Qin F, Song Z, Babiceanu M, Song Y, Facemire L, Singh R, Adli M, Li H.

PLoS Genet. 2015 Feb 6;11(2):e1005001. doi: 10.1371/journal.pgen.1005001. eCollection 2015 Feb.

4.

Genomic rearrangements in prostate cancer.

Barbieri CE, Rubin MA.

Curr Opin Urol. 2015 Jan;25(1):71-6. doi: 10.1097/MOU.0000000000000129.

PMID:
25393273
5.

Transcription-mediated chimeric RNAs in prostate cancer: time to revisit old hypothesis?

Ren G, Zhang Y, Mao X, Liu X, Mercer E, Marzec J, Ding D, Jiao Y, Qiu Q, Sun Y, Zhang B, Yeste-Velasco M, Chelala C, Berney D, Lu YJ.

OMICS. 2014 Oct;18(10):615-24. doi: 10.1089/omi.2014.0042. Epub 2014 Sep 4.

PMID:
25188740
6.

Is an observed non-co-linear RNA product spliced in trans, in cis or just in vitro?

Yu CY, Liu HJ, Hung LY, Kuo HC, Chuang TJ.

Nucleic Acids Res. 2014 Aug;42(14):9410-23. doi: 10.1093/nar/gku643. Epub 2014 Jul 22.

7.

Recurrent read-through fusion transcripts in breast cancer.

Varley KE, Gertz J, Roberts BS, Davis NS, Bowling KM, Kirby MK, Nesmith AS, Oliver PG, Grizzle WE, Forero A, Buchsbaum DJ, LoBuglio AF, Myers RM.

Breast Cancer Res Treat. 2014 Jul;146(2):287-97. doi: 10.1007/s10549-014-3019-2. Epub 2014 Jun 15.

8.

The ETS family member GABPα modulates androgen receptor signalling and mediates an aggressive phenotype in prostate cancer.

Sharma NL, Massie CE, Butter F, Mann M, Bon H, Ramos-Montoya A, Menon S, Stark R, Lamb AD, Scott HE, Warren AY, Neal DE, Mills IG.

Nucleic Acids Res. 2014 Jun;42(10):6256-69. doi: 10.1093/nar/gku281. Epub 2014 Apr 21.

9.

Identification of molecular tumor markers in renal cell carcinomas with TFE3 protein expression by RNA sequencing.

Pflueger D, Sboner A, Storz M, Roth J, Compérat E, Bruder E, Rubin MA, Schraml P, Moch H.

Neoplasia. 2013 Nov;15(11):1231-40.

10.

Aberrant chimeric RNA GOLM1-MAK10 encoding a secreted fusion protein as a molecular signature for human esophageal squamous cell carcinoma.

Zhang H, Lin W, Kannan K, Luo L, Li J, Chao PW, Wang Y, Chen YP, Gu J, Yen L.

Oncotarget. 2013 Nov;4(11):2135-43.

11.

Common fusion transcripts identified in colorectal cancer cell lines by high-throughput RNA sequencing.

Nome T, Thomassen GO, Bruun J, Ahlquist T, Bakken AC, Hoff AM, Rognum T, Nesbakken A, Lorenz S, Sun J, Barros-Silva JD, Lind GE, Myklebost O, Teixeira MR, Meza-Zepeda LA, Lothe RA, Skotheim RI.

Transl Oncol. 2013 Oct 1;6(5):546-53. eCollection 2013.

12.

Integrative transcriptome sequencing identifies trans-splicing events with important roles in human embryonic stem cell pluripotency.

Wu CS, Yu CY, Chuang CY, Hsiao M, Kao CF, Kuo HC, Chuang TJ.

Genome Res. 2014 Jan;24(1):25-36. doi: 10.1101/gr.159483.113. Epub 2013 Oct 16.

13.

Barnacle: detecting and characterizing tandem duplications and fusions in transcriptome assemblies.

Swanson L, Robertson G, Mungall KL, Butterfield YS, Chiu R, Corbett RD, Docking TR, Hogge D, Jackman SD, Moore RA, Mungall AJ, Nip KM, Parker JD, Qian JQ, Raymond A, Sung S, Tam A, Thiessen N, Varhol R, Wang S, Yorukoglu D, Zhao Y, Hoodless PA, Sahinalp SC, Karsan A, Birol I.

BMC Genomics. 2013 Aug 14;14:550. doi: 10.1186/1471-2164-14-550.

14.

Production of ACAT1 56-kDa isoform in human cells via trans-splicing involving the ampicillin resistance gene.

Hu GJ, Chen J, Zhao XN, Xu JJ, Guo DQ, Lu M, Zhu M, Xiong Y, Li Q, Chang CC, Song BL, Chang TY, Li BL.

Cell Res. 2013 Aug;23(8):1007-24. doi: 10.1038/cr.2013.86. Epub 2013 Jul 9.

15.

The genomic landscape of prostate cancer.

Spans L, Clinckemalie L, Helsen C, Vanderschueren D, Boonen S, Lerut E, Joniau S, Claessens F.

Int J Mol Sci. 2013 May 24;14(6):10822-51. doi: 10.3390/ijms140610822. Review.

16.
17.

Recurrent rearrangements in prostate cancer: causes and therapeutic potential.

White NM, Feng FY, Maher CA.

Curr Drug Targets. 2013 Apr;14(4):450-9. Review.

18.

Recurrent reciprocal RNA chimera involving YPEL5 and PPP1CB in chronic lymphocytic leukemia.

Velusamy T, Palanisamy N, Kalyana-Sundaram S, Sahasrabuddhe AA, Maher CA, Robinson DR, Bahler DW, Cornell TT, Wilson TE, Lim MS, Chinnaiyan AM, Elenitoba-Johnson KS.

Proc Natl Acad Sci U S A. 2013 Feb 19;110(8):3035-40. doi: 10.1073/pnas.1214326110. Epub 2013 Feb 4.

19.

Inactivation of ATM/ATR DNA damage checkpoint promotes androgen induced chromosomal instability in prostate epithelial cells.

Chiu YT, Liu J, Tang K, Wong YC, Khanna KK, Ling MT.

PLoS One. 2012;7(12):e51108. doi: 10.1371/journal.pone.0051108. Epub 2012 Dec 18.

20.

Long-range transcriptome sequencing reveals cancer cell growth regulatory chimeric mRNA.

Plebani R, Oliver GR, Trerotola M, Guerra E, Cantanelli P, Apicella L, Emerson A, Albiero A, Harkin PD, Kennedy RD, Alberti S.

Neoplasia. 2012 Nov;14(11):1087-96.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk